CASI Quote, Financials, Valuation and Earnings

China Pharma Holding has a net margin of -107.73% compared to CASI Pharmaceuticals's net margin of -101.61%. CASI Pharmaceuticals's return on equity of -137% beat China Pharma Holding's return on equity of -66.27%.

CASI Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 95.44%. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that CASI Pharmaceuticals has higher upside potential than China Pharma Holding, analysts believe CASI Pharmaceuticals is more attractive than China Pharma Holding.

CASI Pharmaceuticals has a beta of 0.544, which suggesting that the stock is 45.577% less volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.874%.

CASI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CASI Pharmaceuticals pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

CASI Pharmaceuticals quarterly revenues are $7.8M, which are larger than China Pharma Holding quarterly revenues of $1.1M. CASI Pharmaceuticals's net income of -$8.4M is lower than China Pharma Holding's net income of -$1.1M. Notably, CASI Pharmaceuticals's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals is 1.93x versus 0.54x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

LakeShore Biopharma has a net margin of -107.73% compared to CASI Pharmaceuticals's net margin of --. CASI Pharmaceuticals's return on equity of -137% beat LakeShore Biopharma's return on equity of -7.94%.

CASI Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 95.44%. On the other hand LakeShore Biopharma has an analysts' consensus of -- which suggests that it could grow by 781.96%. Given that LakeShore Biopharma has higher upside potential than CASI Pharmaceuticals, analysts believe LakeShore Biopharma is more attractive than CASI Pharmaceuticals.

CASI Pharmaceuticals has a beta of 0.544, which suggesting that the stock is 45.577% less volatile than S&P 500. In comparison LakeShore Biopharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CASI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LakeShore Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CASI Pharmaceuticals pays -- of its earnings as a dividend. LakeShore Biopharma pays out -- of its earnings as a dividend.

CASI Pharmaceuticals quarterly revenues are $7.8M, which are larger than LakeShore Biopharma quarterly revenues of --. CASI Pharmaceuticals's net income of -$8.4M is higher than LakeShore Biopharma's net income of --. Notably, CASI Pharmaceuticals's price-to-earnings ratio is -- while LakeShore Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals is 1.93x versus 0.57x for LakeShore Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -107.73% compared to CASI Pharmaceuticals's net margin of --. CASI Pharmaceuticals's return on equity of -137% beat Sinovac Biotech's return on equity of -1.05%.

CASI Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 95.44%. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that CASI Pharmaceuticals has higher upside potential than Sinovac Biotech, analysts believe CASI Pharmaceuticals is more attractive than Sinovac Biotech.

CASI Pharmaceuticals has a beta of 0.544, which suggesting that the stock is 45.577% less volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CASI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CASI Pharmaceuticals pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

CASI Pharmaceuticals quarterly revenues are $7.8M, which are larger than Sinovac Biotech quarterly revenues of --. CASI Pharmaceuticals's net income of -$8.4M is higher than Sinovac Biotech's net income of --. Notably, CASI Pharmaceuticals's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals is 1.93x versus 1.50x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of -107.73% compared to CASI Pharmaceuticals's net margin of -40.75%. CASI Pharmaceuticals's return on equity of -137% beat Zai Lab's return on equity of -35.53%.

CASI Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 95.44%. On the other hand Zai Lab has an analysts' consensus of $52.39 which suggests that it could grow by 92.48%. Given that CASI Pharmaceuticals has higher upside potential than Zai Lab, analysts believe CASI Pharmaceuticals is more attractive than Zai Lab.

CASI Pharmaceuticals has a beta of 0.544, which suggesting that the stock is 45.577% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.054%.

CASI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CASI Pharmaceuticals pays -- of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend.

CASI Pharmaceuticals quarterly revenues are $7.8M, which are smaller than Zai Lab quarterly revenues of $102.3M. CASI Pharmaceuticals's net income of -$8.4M is higher than Zai Lab's net income of -$41.7M. Notably, CASI Pharmaceuticals's price-to-earnings ratio is -- while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CASI Pharmaceuticals is 1.93x versus 7.46x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.